Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01510418 · ClinicalTrials.gov registry record

Socialization of Adult Men With Congenital Hemophilia A or B

A clinical trial, sponsored by Dana-Farber Cancer Institute.

Completed
Registry status
27
Enrollment target

NCT01510418 is a clinical trial that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 27 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01510418 has completed, sponsored by Dana-Farber Cancer Institute.

COMPLETED
Registry status
27 participants
Enrollment target

Study Summary

The goal of this pilot study is to understand the socialization of adult men with hemophilia living in the United States and their quality of life in order to improve comprehensive care for persons with congenital bleeding disorders. Studies in Europe suggest that despite medical, surgical, and biotechnology advances in care for persons with the congenital bleeding disorders hemophilia A and B, men with hemophilia have earlier work disability and health-related lower quality of life than men of the same age who do not have hemophilia in the general population. Congenital bleeding disorders are known to have medical and psychosocial impact not only in school but also in other activities, e.g. participation in sports beginning at a young age. The psychosocial impact of living with a congenital bleeding disorder has been studied and described in childhood. The support relationships in childhood include parents and primary family of origin and these supports are generally considered in pediatric comprehensive care models. Support relationships in adulthood have not been well described or studied. The role of spouse and significant others (SSO) of PWCBD in health care is of interest for the delivery of adult comprehensive care as well as to understand their contribution to the health-related quality of life of PWCBD. Additionally, this study seeks to learn of the impact of congenital bleeding disorders for the SSO. The study uses self-reported medical and social information questionnaires, health-related quality of life surveys, and confidential interview. Results of this study may guide how comprehensive care and support are provided to adult persons with congenital bleeding disorders by hemophilia treatment programs. This study focuses on PWCBD with hemophilia A or B as a model for the experience of persons with other congenital bleeding disorders.

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2011-05
Est. Completion 2013-12

Sponsor

Dana-Farber Cancer Institute

781 total trials

What the Registry Record Tells You About NCT01510418

The ClinicalTrials.gov registry entry for NCT01510418 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT01510418 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01510418 about?

NCT01510418 is a clinical study titled "Socialization of Adult Men With Congenital Hemophilia A or B". The goal of this pilot study is to understand the socialization of adult men with hemophilia living in the United States and their quality of life in order to improve comprehensive care for persons with congenital bleeding disorders. Studies in Europe suggest that despite medical, surgical, and biot...

What is the current status of trial NCT01510418?

This trial is currently completed. The enrollment target is 27 participants. The study started on 2011-05. Estimated completion is 2013-12.

Who is sponsoring clinical trial NCT01510418?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.